Summary We show that imatinib nilotinib and dasatinib possess weak off-target activity against RAF and therefore drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. tyrosine kinase. The normal function(s) of BCR are unclear but ABL is a…